NCT04963153 2026-04-13Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and ImmunotherapyNational Cancer Institute (NCI)Phase 1 Active not recruiting24 enrolled
NCT07484022 2026-04-07Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial CancerGenerate BiomedicinesPhase 1 Recruiting37 enrolled